1. U.S. FDA., 2012. FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses.
2. Medicines and Healthcare products Regulatory Agency., 2014. Citalopram and escitalopram: QT interval prolongation-New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Published 11 December 2014. Medicines and Healthcare products Regulatory Agency.
3. Health Canada., 2012. Antidepressant cipralex (escitalopram): updated information regarding dose-related heart risk.
4. Allergan USA, Inc. Lexapro® (escitalopram oxalate) [Prescribing Information]. 2017. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf (accessed on December 2019).
5. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation;Akil;J. Pharmacokinet. Pharmacodyn.,2016